New DoseSpot Analysis of 100,000 GLP-1 Prescriptions Finds That Patients Overpaid by $10.2M Collectively
92 percent of prescriptions could have been filled at a lower price, with better information on pricing, dispensing options and manufacturer cost-savings programs DoseSpot, which delivers best-in-class e-prescribing, insurance verification and revenue cycle management solutions for healthcare providers, announced today the results of a new data analysis on 102,166 GLP-1 prescriptions the company processed in Q1 2025. […]
✨ GLP-1s and Post-Weight Loss Plastic Surgery Trends
There is growing evidence—especially in the plastic surgery community—that the recent surge in GLP‑1 medications (like Ozempic, Wegovy, Mounjaro) for weight loss is fueling a wave of “trim & sculpt” surgeries to address excess skin and volume loss. 📈 Trend & Clinical ReviewsThe American Society of Plastic Surgeons and multiple industry blogs report an increase […]
Viking Therapeutics: What’s Next After GLP-1 Hype Dies Down And Competition Intensifies
Weight loss drugs linked with growing number of side effects
The longer weight loss GLP-1 drugs like Ozempic and Wegovy have been on the market, the more side effects people are reporting. In very rare cases they can be deadly. Here’s what to know.
Viking Therapeutics: What’s Next After GLP-1 Hype Dies Down And Competition Intensifies
Glucagon‐like peptide‐1 is involved in fasting and postprandial blood flow regulation of subcutaneous adipose tissue
Abstract Aims Glucagon-like peptide 1 (GLP-1) is a gastrointestinal hormone with pleiotropic functions, including vasodilatory and vasculoprotective effects. As GLP-1 increases after a meal, it could be involved in adipose tissue blood flow (ATBF) regulation. In one-third of healthy people, the postprandial ATBF response to meals is blunted. Whether this responder/non-responder phenomenon stems from an […]
Opinion: STAT+: How to evaluate GLP-1s and Medicare costs? Here’s one idea
Today, more than 40% of adults over 60 are considered obese, fueling chronic disease and straining Medicare’s budget. With the price tag for obesity-related care rising, some experts suggest covering GLP-1 medications for weight loss through Medicare could save billions, citing data that estimates Medicare spending could drop by $1,262 to $5,442 annually per beneficiary […]
Ozempic and Other GLP-1 Side Effects May Outweigh the Benefits
Learn how the benefits of GLP-1s may be outweighed by the risks.
Ciba Health Launches Nation’s First GLP-1 Step-Down Program, Addressing Post-Medication Metabolic Health
What You Should Know: – Ciba Health today announced the launch of its new GLP-1 Step-Down Program, marking the first national offering designed to guide individuals off popular weight loss medications like Ozempic and Wegovy. – Ciba Health’s virtual program aims to help members either avoid GLP-1 medications entirely or safely taper off them by […]
Is Novo Nordisk Increasing Dosage to Defend Wegovy’s Edge in Obesity?
Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking approval for a new and higher dose of its popular obesity medication, Wegovy (subcutaneous semaglutide 7.2 mg). Wegovy is also indicated for major adverse cardiovascular events risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain […]